Yang Fei, Gao Jun-Yi, Chen Hua, Du Zhen-Hua, Zhang Xue-Qun, Gao Wei
Department of Pathology, Jinan Central Hospital Affiliated to Shandong University, Jinan.
Department of Clinical Medicine, Weifang Medical College, Weifang.
Onco Targets Ther. 2017 Sep 11;10:4413-4422. doi: 10.2147/OTT.S145601. eCollection 2017.
Colon cancer is the third most common cancer in the world, and its metastasis and drug resistance are challenging for its effective treatment. The PI3K/Akt/mTOR pathway plays a crucial role in the pathogenesis of colon cancer. The aim of this study was to investigate the targeting of PI3K in colon cancer cells HT-29 and HCT-116 in vitro.
In HT-29 and HCT-116 cells, BEZ235, a dual inhibitor of PI3K/mTOR, and shRNAtarget to PI3KCA were used to inhibit PI3K/Akt/mTOR pathway. The inhibition efficiency of PI3K/Akt/mTOR pathway was detected by RT-PCR and Western blot. Cell proliferation, migration, invasion, and apoptosis were evaluated by Cell Counting Kit-8, Transwell, and flow cytometry assays. The expression of apoptosis-related proteins (cleavage caspase 3, Bcl-2, Bax, and Bim) were also detected.
We found that in HT-29 and HCT-116 cells, the treatment of BEZ235 (1 μM) and PI3KCA knockdown inhibited the activation of PI3K/Akt/mTOR pathway and significantly suppressed cell proliferation, migration, and invasion of HT-29 and HCT-116 cells. In addition, we confirmed that knockdown of BEZ235 and PI3KCA induced cell apoptosis through the upregulated levels of cleavage caspase 3 and Bax and downregulated expression of Bcl-2 and Bim.
Our results indicated that targeted inhibition of the PI3K/Akt/mTOR pathway impaired cell proliferation, survival, and invasion in human colon cancer.
结肠癌是全球第三大常见癌症,其转移和耐药性对有效治疗构成挑战。PI3K/Akt/mTOR通路在结肠癌的发病机制中起关键作用。本研究旨在体外研究PI3K在结肠癌细胞HT - 29和HCT - 116中的靶向作用。
在HT - 29和HCT - 116细胞中,使用PI3K/mTOR双重抑制剂BEZ235和针对PI3KCA的短发夹RNA(shRNA)来抑制PI3K/Akt/mTOR通路。通过RT - PCR和蛋白质免疫印迹法检测PI3K/Akt/mTOR通路的抑制效率。通过细胞计数试剂盒 - 8、Transwell实验和流式细胞术检测细胞增殖、迁移、侵袭和凋亡情况。还检测了凋亡相关蛋白(裂解的半胱天冬酶3、Bcl - 2、Bax和Bim)的表达。
我们发现,在HT - 29和HCT - 116细胞中,用BEZ235(1μM)处理和敲低PI3KCA可抑制PI3K/Akt/mTOR通路的激活,并显著抑制HT - 29和HCT - 116细胞的增殖、迁移和侵袭。此外,我们证实敲低BEZ235和PI3KCA可通过上调裂解的半胱天冬酶3和Bax的水平以及下调Bcl - 2和Bim的表达诱导细胞凋亡。
我们的结果表明,靶向抑制PI3K/Akt/mTOR通路会损害人结肠癌细胞的增殖、存活和侵袭。